STA
ENTA icon

Summit Trail Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Summit Trail Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10
Closed -$1K – 799
2017
Q4 		$1K Buy
+10
New +$501 ﹤0.01% 1786

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Summit Trail Advisors's ENTA Position: Q1 2018 in Review

Summit Trail Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2018, closing a stake of 10 shares — an estimated $1K sold.

Summit Trail Advisors first reported a position in ENTA in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 181 funds tracked by Wall St. Rank hold ENTA as of Q1 2018.

  • Summit Trail Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 10 Enanta Pharmaceuticals shares in Q1 2018, an estimated $1K.
  • Summit Trail Advisors first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Summit Trail Advisors's Enanta Pharmaceuticals position peaked at $1K in Q4 2017.
  • 181 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.